https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15187 Wed 14 Aug 2024 10:31:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18015 Wed 11 Apr 2018 11:16:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20161 Tue 24 Aug 2021 14:24:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8052 Sat 24 Mar 2018 08:35:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7618 Sat 24 Mar 2018 08:34:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27185 Sat 24 Mar 2018 07:31:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30671 95% in both groups. GPs and their patients both found the GPCOG to be an acceptable cognitive assessment tool. The dementia cases missed via case-finding were younger (p = 0.024) and less cognitively impaired (p = 0.020) than those detected. Conclusion: There is a very limited benefit of screening for dementia, as most people with dementia could be detected using a case-finding approach, and considerable potential for social and economic harm because of the low PPV associated with screening.]]> Sat 24 Mar 2018 07:29:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26028 Sat 24 Mar 2018 07:26:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22233 Sat 24 Mar 2018 07:17:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40610 n = 1768), at year one (n = 1373) and a restricted cohort (with possible or definite cognitive impairment) at year two (n = 370) had medication regimens documented by a research nurse during a home visit. Anticholinergic medicines were categorized as levels 1-3 (low-high potency) and summed for each participant as a measure of their ACL. RESULTS: Most participants had no change in ACL over time, but there was some turnover in the anticholinergic medications used. The mean change in ACL was 0.012 ± 0.99 from baseline to 12 months and −0.04 ± 1.3 from baseline to 24 months. Cardiovascular drugs were the most commonly used level 1 anticholinergics, followed by antidepressants and opioids. Antidepressants and urologicals were the most commonly used level 3 anticholinergics. The rate of anticholinergic deprescribing was equivalent to the rate of anticholinergic initiation, and commonly involved the level 1 drugs warfarin, furosemide and temazepam, and the level 3 drugs amitriptyline and oxybutynin. People with dementia had a higher ACL at baseline and year one compared with other participants. CONCLUSION: ACL of community-dwelling older people was very stable over time. This may represent lost opportunities for deprescribing as well as potentially inappropriate prescribing, particularly in those with cognitive impairment.]]> Fri 15 Jul 2022 11:49:13 AEST ]]>